Punch & Associates Investment Management’s Royalty Pharma RPRX Stock Holding History

Punch & Associates Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5M	Sell	597,938 -679	-0.1%	-$35.3K	1.66%	14
2026 Q1	$28.7M	Sell	598,617 -1,549	-0.3%	-$67.8K	1.66%	11
2025 Q4	$23.2M	Buy	600,166 +4,275	+0.7%	+$163K	1.35%	19
2025 Q3	$21M	Sell	595,891 -72	-0%	-$2.61K	1.22%	23
2025 Q2	$21.5M	Buy	595,963 +22,360	+4%	+$741K	1.32%	16
2025 Q1	$17.9M	Buy	573,603 +101,390	+21%	+$3.21M	1.17%	20
2024 Q4	$12M	Buy	472,213 +11,162	+2%	+$296K	0.66%	58
2024 Q3	$13M	Buy	461,051 +36,510	+9%	+$1.01M	0.72%	45
2024 Q2	$11.2M	Buy	424,541 +55,625	+15%	+$1.54M	0.65%	55
2024 Q1	$11.2M	Buy	+368,916	New	+$10.9M	0.64%	59

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Punch & Associates Investment Management's RPRX Position: Q2 2026 in Review

Punch & Associates Investment Management reduced its Royalty Pharma (RPRX) stake by 0.11% in Q2 2026, selling an estimated $35.3K and leaving 597,938 shares worth $33.5M. The position accounts for 1.66% of the portfolio, ranked #14.

Punch & Associates Investment Management first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Punch & Associates Investment Management held 597,938 shares of Royalty Pharma worth $33.5M as of Q2 2026.
Punch & Associates Investment Management sold 679 Royalty Pharma shares in Q2 2026, an estimated $35.3K.
Royalty Pharma made up 1.66% of Punch & Associates Investment Management's portfolio in Q2 2026, its #14 holding.
Punch & Associates Investment Management first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Punch & Associates Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.